Lv41
500 积分 2021-11-11 加入
Rapid Advances in Resectable Non–Small Cell Lung Cancer
7分钟前
已完结
Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making
8分钟前
待确认
Non-small-cell lung cancer
9分钟前
已完结
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives
12分钟前
待确认
Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non–Small Cell Lung Cancer
16分钟前
已完结
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
21分钟前
待确认
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
24分钟前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
1小时前
已完结
Neoadjuvant Concurrent Chemo–Immuno–Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)
1小时前
已完结
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
1小时前
已完结
皖公网安备34019202002308
